Bayer Links
Copyright ©
Bayer HealthCare AG
News archive
LEVITRA 10mg Orodispersible Tablet for the Treatment of Erectile Dysfunction approved in Europe
New formulation expected to be launched in November 2010 » more
TALENT Study Shows: Starting with a Combination of Adalat® GITS and Pritor®/Kinzal® Achieves Earlier Blood Pressure Control than Initiating Monotherapy with Either Combination Component
First study ever to examine blood pressure-lowering efficacy of the combination of nifedipine (Adalat® GITS) with telmisartan (Pritor®/Kinzal®) » more
Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study
Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 » more
Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use
Bayer’s dermatology subsidiary Intendis prepares to enter aesthetics segment / Joint development of first-in-class injectable drug for minimally invasive facial fat reduction » more
Insights on Benefits versus Risks of Low-dose Aspirin in Reducing Cardiovascular Disease
Impact of global, regional CVD burden / Importance of targeted primary prevention therapy to reduce the global CVD burden / Large existing body of primary prevention evidence for aspirin in appropriate patients » more
Bayer’s Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT Study
Rivaroxaban shows superiority to standard therapy in net clinical benefit, a secondary endpoint of the study / Rivaroxaban well tolerated in this long-term trial / Full data set to be presented at Hot Line Session at ESC 2010 » more
FDA Accepts New Drug Application for Gadovist® 1.0 Injection in Magnetic Resonance Imaging
Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance imaging » more
Bayer increases sales and earnings in the second quarter
Sales grow by 14.6 percent to EUR 9,179 million / EBITDA before special items up 8.6 percent to EUR 1,917 million / Core earnings per share increase by 9.5 percent to EUR 1.15 / Investing in the future: research and development expenses in 2010 to reach a new high of approximately EUR 3.1 billion / Group outlook confirmed for 2010 » more
YAZ® approved in Japan for the treatment of dysmenorrhea
Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ® » more
Bayer Animal Health showcases global commitment to transform livestock production at IPVS
Bayer’s practical ingenuity ensures veterinarians and producers are equipped for successful swine production in highly competitive globalised marketplace » more
“Advances in Renal Cancer” Journalists’ Award 2011 announced
Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer » more
Bayer Schering Pharma enters strategic partnership with The People’s Liberation Army General Hospital in China
Special focus on joint research programs in the field of gynecological diseases » more
Experts confirm favorable benefit-risk profile of combined oral contraceptives
Combined oral contraceptives are one of the safest, most reliable and most convenient options to prevent unplanned pregnancies / All combined oral contraceptives are associated with an increased risk of venous thromboembolism / Risk factor information is essential in deciding whether a combined oral contraceptive is a suitable contraceptive choice » more
“European Bayer Award for Best Scientific Poster Abstract” announced
Bayer HealthCare honors outstanding work and pivotal role of diabetes nurses » more
Bayer Animal Health and Paraco agree on access to lead molecules
Bayer Animal Health GmbH and Paraco Technology Limited today announced they have signed an option agreement allowing Bayer exclusive access to Paraco’s current lead molecules for testing and development in animal health. » more
New edition of “Names, Figures, Facts”
Service line for free booklet » more
European Journalists’ Prize goes to Martin Thür and Dr. Hellmuth Nordwig
Award sponsored by the Association of German Medical Journalists (VDMJ) and Bayer HealthCare AG » more
Information-motivation-behavior skills analysis advance understanding of barriers to self-monitoring of blood glucose
Utilization of IMB skills model for understanding SMBG may be useful for overcoming obstacles to adherence » more
New erectile dysfunction treatment STAXYN™ approved in the U.S.
Orodispersible formulation of Levitra® (vardenafil HCI) soon available » more
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Collaboration Focuses on the Discovery and Development of Multiple Antibody, Protein and Small Molecule Agents Targeting the Wnt Pathway » more
Bayer sues Teva and Barr for false advertising and patent infringement in connection with Teva’s generic oral contraceptive Gianvi™
Gianvi™’s label falsely claims that its formula and product, now in the US market, contains the same product stabilizer as YAZ® (drospirenone & ethinyl estradiol) Bayer’s oral contraceptive / Suit filed in the Northern District of Illinois (Chicago) » more
Phase III Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Positive Secondary Endpoint of Progression Free Survival / Clinical Trial Program in Lung Cancer Ongoing » more
Study Supports Long-Term Safety Profile of Betaferon® for Multiple Sclerosis Over 16 Years
Study results published in Neurology provide the longest follow-up data among patients with multiple sclerosis » more
Take a peek at the undercover world of parasites
Launch of online video tour showcases the fascinating world of parasites » more
Bayer Presents New Riociguat Phase II Data
First Phase II study in patients with pulmonary hypertension owing to interstitial lung disease meets primary objectives / First long-term extension data of Phase II study in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension show sustained improvement in exercise capacity » more
Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center
New U.S. Innovation Center in San Francisco’s Mission Bay will focus on developing partnerships with academic research institutions and small life science firms » more
Bayer receives approval for its new oral contraceptive in the U.S.
The first and only contraceptive to bring estradiol valerate together with dienogest in a new dosing regimen / Product will be marketed as Natazia® in the U.S. » more
Search
Page tools
click to adjust font size
Social Bookmarks
Bayer HealthCare Links
Country Website
